References

• 1. Lan Z, Li X, Zhang X. Glioblastoma: An update in pathology, molecular mechanisms and biomarkers. Int J Mol Sci 2024; 25(5): 3040. google scholar
• 2. Bou-Gharios J, Noel G, Burckel H. Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme. Cell Death Dis 2024; 15(7): 503. google scholar
• 3. Aghajani M, Jalilzadeh N, Aghebati-Maleki A, Yari A, Tabnak P, Mardi A, et al. Current approaches in glioblastoma multiforme immunotherapy. Clin Transl Oncol 2024; 26(7): 1584-612. google scholar
• 4. Shahcheraghi SH, Alimardani M, Lotfi M, Uversky VN, Guetchueng ST, Palakurthi SS, et al. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives. Pathol Res Pract 2024; 257: 155285. google scholar
• 5. Lorimer I. Modeling glioblastoma. eLife 2024; 13: e100824. google scholar
• 6. Wu H, Guo C, Wang C, Xu J, Zheng S, Duan J, et al. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. Cancer Sci 2023; 114(6): 2609-21. google scholar
• 7. Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021; 1876(2): 188616. google scholar
• 8. Cortes Ballen AI, Amosu M, Ravinder S, Chan J, Derin E, Slika H, et al. Metabolic reprogramming in glioblastoma multiforme: A review of pathways and therapeutic targets. Cells 2024; 13(18): 1574. google scholar
• 9. Sarkar S, Patranabis S. Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches. Hum Cell 2024; 37(5): 1355-1377. google scholar
• 10. Barzegar Behrooz A, Talaie Z, Jusheghani F, tos MJ, Klonisch T, Ghavami S. Wnt and PI3K/Akt/mTOR survival pathways as therapeutic targets in glioblastoma. Int J Mol Sci 2022; 23(3): 1353. google scholar
• 11. Jena L, McErlean E, McCarthy H. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res 2020; 10(2): 304-18. google scholar
• 12. Song X, Qian H, Yu Y. Nanoparticles mediated the diagnosis and therapy of glioblastoma: bypass or cross the blood-brain barrier. Small 2023; 19(45): e2302613. google scholar
• 13. Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, et al. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol 2020; 11: 582106. google scholar
• 14. Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev 2019; 48(11): 2967-3014. google scholar
• 15. Kılıç T, Yıldırım Ö, Şahin S, Pamir MN. Glial tümörlerin anjiogenezi. Turk Neurosurg 2005; 15(1): 1-9. google scholar
• 16. Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro Oncol 2018; 20(11): 1462-74. google scholar
• 17. Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol 2017; 133(3): 455-67. google scholar
• 18. Arora H, Mammi M, Patel NM, Zyfi D, Dasari HR, Yunusa I, et al. Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis. J Neurooncol 2024; 166(1): 17-26. google scholar
• 19. Pasupuleti V, Vora L, Prasad R, Nandakumar DN, Khatri DK. Glioblastoma preclinical models: strengths and weaknesses. Biochim Biophys Acta Rev Cancer 2024; 1879(1): 189059. google scholar
• 20. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 2020; 6(7): 1003-10. google scholar
• 21. Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol 2023; 41(6): 1285-95. google scholar
• 22. Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, et al. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 2019; 110(2): 499-508. google scholar
• 23. De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity 2024; 57(5): 1105-23.e8. google scholar
• 24. Rashidi A, Billingham LK, Zolp A, Chia TY, Silvers C, Katz JL, et al. Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. Cell Metab 2024; 36(1): 62-77.e8. google scholar
• 25. Stadlbauer A, Roessler K, Zimmermann M, Buchfelder M, Kleindienst A, Doerfler A, et al. Predicting glioblastoma response to bevacizumab through MRI biomarkers of the tumor microenvironment. Mol Imaging Biol 2019; 21(4): 747-57. google scholar
• 26. Fathi M, Razavi SM, Sojoodi M, Ahmadi A, Ebrahimi F, Namdar A, et al. Targeting the CTLA-4/B7 axes in glioblastoma: Preclinical evidence and clinical interventions. Expert Opin Ther Targets 2022; 26(11): 949-61. google scholar
• 27. de Cristo Soares Alves A, Lavayen V, de Fraga Dias A, Bruinsmann FA, Scholl JN, Ce R, et al. EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: A nose-to-brain multitarget approach against glioblastoma. Nanomedicine (Lond) 2021; 16(20): 1775-90. google scholar
• 28. Cai Q, Li X, Xiong H, Fan H, Gao X, Vemireddy V, et al. Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment. Nat Commun 2023; 14(1): 4934. google scholar
• 29. Mauldin IS, Jo J, Wages NA, Yogendran LV, Mahmutovic A, Young SJ, et al. Proliferating CD8+ T cell infiltrates are associated with improved survival in glioblastoma. Cells 2021; 10(12): 3378. google scholar
• 30. Jimenez-Pascual A, Mitchell K, Siebzehnrubl FA, Lathia JD. FGF2: A novel druggable target for glioblastoma? Expert Opin Ther Targets 2020; 24(4): 311-8. google scholar
• 31. Singh RR, Mondal I, Janjua T, Popat A, Kulshreshtha R. Engineered smart materials for RNA based molecular therapy to treat glioblastoma. Bioact Mater 2023; 33: 396-423. google scholar
• 32. Wiwatchaitawee K, Quarterman JC, Geary SM, Salem AK. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech 2021; 22(2): 71. google scholar
• 33. Ruiz-Garcia H, Ramirez-Loera C, Malouff TD, Seneviratne DS, Palmer JD, Trifiletti DM. Novel strategies for nanoparticle-based radiosensitization in glioblastoma. Int J Mol Sci 2021; 22(18): 9673. google scholar
• 34. Lakshmi BA, Kim YJ. Modernistic and emerging developments of nanotechnology in glioblastoma-targeted theranostic applications. Int J Mol Sci 2022; 23(3): 1641. google scholar
• 35. Jena L, McErlean E, McCarthy H. Delivery across the blood-brain barrier: Nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res 2020; 10(2): 304-18. google scholar
• 36. She L, Su L, Liu C. Bevacizumab combined with re-irradiation in recurrent glioblastoma. Front Oncol 2022; 12: 961014. google scholar
• 37. Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, et al. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. Semin Cancer Biol 2022; 83: 100-20. google scholar
• 38. Cui X, Huo D, Wang Q, Wang Y, Liu X, Zhao K, et al. RUNX1/NPM1/ H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma. Cell Death Dis 2024; 15(1): 98. google scholar
• 39. Mahmoud AB, Ajina R, Aref S, Darwish M, Alsayb M, Taher M, et al. Advances in immunotherapy for glioblastoma multiforme. Front Immunol 2022; 13: 944452. google scholar
• 40. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2023; 41(32): 4945-52. google scholar
• 41. Collado J, Boland L, Ahrendsen JT, Miska J, Lee-Chang C. Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy. Front Immunol 2024; 15: 1336476. google scholar
• 42. Chamarthy S, Mekala JR. Functional importance of glucose transporters and chromatin epigenetic factors in glioblastoma multiforme (GBM): possible therapeutics. Metab Brain Dis 2023; 38(5): 1441-69. google scholar
• 43. Abdi F, Arkan E, Eidizadeh M, Valipour E, Naseriyeh T, Gamizgy YH, et al. The possibility of angiogenesis inhibition in cutaneous melanoma by bevacizumab-loaded lipid-chitosan nanoparticles. Drug Deliv Transl Res 2023; 13(2): 568-79. google scholar
• 44. Khan MA, Kalsoom S, Ayub AR, Ilyas M, Hassan N, Irshad K, et al. Host-guest coupling to potentially increase the bio-accessibility of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by nanocarrier graphyne for brain tumor therapy, a comprehensive quantum mechanics study. J Mol Graph Model 2023; 123: 108517. google scholar
• 45. Tensaouti F, Desmoulin F, Gilhodes J, Roques M, Ken S, Lotterie JA, et al. Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival? Radiother Oncol 2023; 183: 109665. google scholar
• 46. Liang HT, Mizumoto M, Ishikawa E, Matsuda M, Tanaka K, Kohzuki H, et al. Peritumoral edema status of glioblastoma identifies patients reaching long-term disease control with specific progression patterns after tumor resection and high-dose proton boost. J Cancer Res Clin Oncol 2021; 147(12): 3503-16. google scholar
• 47. Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, et al. Off-the-shelf, steroid-resistant, IL13Ra2-specific CAR T cells for treatment of glioblastoma. Neuro Oncol 2022; 24(8): 1318-30. google scholar
• 48. Jo J, Wen PY. Antiangiogenic therapy of high-grade gliomas. Prog Neurol Surg 2018; 31: 180-99. google scholar
• 49. Kim MM, Umemura Y, Leung D. Bevacizumab and glioblastoma: Past, present, and future directions. Cancer J 2018; 24(4): 180-6. google scholar
• 50. Carvalho B, Lopes JM, Silva R, Peixoto J, Leitâo D, Soares P, et al. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Sci Rep 2021; 11: 6067. google scholar

Citations